Company intelligence / Profile preview
REGENXBIO Inc.
Rockville, Maryland, United States of Americaregenxbio.com ↗
- Ownership
- Public · RGNX
- Employees
- ~353
- Development stage
- Other
01
Overview
REGENXBIO has multiple clinical programs showing promising results. RGX-202 for Duchenne has demonstrated robust microdystrophin expression with good tolerability. RGX-121 for MPS II has advanced to BLA filing. ABBV-RGX-314 for wet AMD is progressing toward global regulatory submissions.
- Therapeutic areas
- OphthalmologyImmunologyRare DiseasesNeurology
- Modalities
- Gene therapyAAV-mediated antibody delivery
- Industry
- Biotech
02
Drug pipeline
12 assets11 more assets in the full pipeline.
03
Partnerships
AbbVie (eye care collaboration)Nippon Shinyaku Co., Ltd. (for RGX-121 and RGX-111)Neurimmune (for neurodegenerative diseases)Ultragenyx Pharmaceutical Inc.
04
Financials
- Market cap
- $487.2M
- Total revenue
- $170.4M
- Enterprise value
- $302.7M
Beyond the preview
Go deeper on REGENXBIO Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on REGENXBIO Inc..